Involvement of the ERK1/2 MAPK pathway in insulin-induced S6K1 activation in avian cells.
In mammals, insulin regulates S6K1, a key enzyme involved in the control of protein synthesis, via the well-documented phosphoinositide-3'kinase (PI3K) pathway. Conversely, S6K1 is activated by insulin in avian muscle despite the relative insulin insensitivity of the PI3K pathway in this tissue. Mitogen-activated protein kinase (MAPK) cascade is another insulin sensitive pathway. The aim of this study was to explore the potential involvement of the ERK1/2 MAPK pathway in the control of p70 S6 kinase (S6K1) in avian species. Firstly, we characterized ERK1/2 MAPK in various chicken tissues. ERK2 was the only isoform detected in avian species whatever the tissue studied. We also showed that ERK2 is activated in vivo by insulin in chicken muscle. The regulation and the role of ERK2 in insulin signaling were next investigated in chicken hepatoma cells (LMH) and primary myoblasts. Insulin stimulation led to ERK2 and S6K1 phosphorylation, and concomitantly increased kinase activity. U0126, an inhibitor of the ERK MAPK pathway, completely abolished insulin-induced S6K1 phosphorylation and activity in chicken myoblasts, whereas its effect was only partial in LMH cells. In conclusion, these results show that ERK1/2 MAPK is involved in the control of S6K1 by insulin in chicken cells, particularly myoblasts.
Duchêne
Sophie
S
UR83 Recherches Avicoles, INRA, 37380 Nouzilly, France.
Audouin
Estelle
E
Crochet
Sabine
S
Duclos
Michel J
MJ
Dupont
Joëlle
J
Tesseraud
Sophie
S
D000818:Animals; D015153:Blotting, Western / Q000662:veterinary; D002070:Butadienes / Q000494:pharmacology; D045744:Cell Line, Tumor; D002645:Chickens / Q000378:metabolism*; D002867:Chromones / Q000494:pharmacology; D004789:Enzyme Activation; D007328:Insulin / Q000378:metabolism / Q000494:pharmacology*; D008114:Liver Neoplasms, Experimental; D020935:MAP Kinase Signaling System; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009025:Morpholines / Q000494:pharmacology; D032448:Myoblasts, Skeletal / Q000201:enzymology; D009570:Nitriles / Q000494:pharmacology; D010369:Pectoralis Muscles / Q000201:enzymology*; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000662:veterinary; D019893:Ribosomal Protein S6 Kinases / Q000235:genetics / Q000378:metabolism*
D002070:Butadienes; D002867:Chromones; D007328:Insulin; D009025:Morpholines; D009570:Nitriles; D047428:Protein Kinase Inhibitors; C113580:U 0126; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D019893:Ribosomal Protein S6 Kinases; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3